Scientists of the Russian nuclear industry want to conduct preclinical studies they have developed a promising radiopharmaceutical for diagnosis of the lung condition severe deficiencies, including observed on the background of coronavirus infection, the materials on the procurement website of Rosatom state Corporation.
According to these materials, the specialists of “radium Institute named after Khlopina” (Saint-Petersburg, is included in the scientific division of “Rosatom”) at the request of the management company the science division of the nuclear power Corporation JSC “Science and innovations” must prepare a technical specification for preclinical studies of innovative bifunctional radiopharmaceutical drug pentacarbonyliron of technetium-99m for the diagnosis of perfusion and ventilation.
For a complete study of the condition of the lungs with the help of radiopharmaceuticals are used for two treatments: intravenous administration of a suitable drug (in the study of perfusion – blood flow in the lung tissue) and inhalation of gaseous radioactive drug (in the study of ventilation – exchange of air between lungs and the atmosphere). This diagnostic method is needed to identify dangerous diseases such as pulmonary embolism, hypertension of the pulmonary circulation, thrombosis of the veins of the shoulder girdle, chronic obstructive pulmonary disease, etc.
Separate big challenge for medicine in recent years is the diagnostics of a condition of the lungs in patients with coronavirus infection, one of the extremely dangerous complication is pulmonary embolism.
Currently conducting a full investigation of the lungs because of several reasons, is quite complex and, moreover, costly. Thus, the search of the drug which to study perfusion and ventilation, is an urgent task, which will help to simplify and reduce the cost of diagnosis.
Designed in the “radium Institute” new drug pentacarbonyliron technetium-99m (SCIT-99mTc), as shown by preliminary studies on laboratory animals, with high selectivity accumulate in lung tissue and thus suitable for the study of both perfusion and ventilation. The SCIT-99mTc lacks the disadvantages of the radiopharmaceuticals drugs, now applied to the study of light. As noted in the technical task of the present work, before such drug existed.
Preliminary experiments on model animals revealed that the new drug is not toxic. The introduction into clinical practice of SCIT-99mTc will allow, on the one hand, significantly reduce the diagnostic procedure of the lungs, and on the other hand is to eliminate the disadvantages of pulmonary drugs currently used, as stated in the terms of reference. Preclinical studies are planned in St. Petersburg the Russian scientific center of radiology and surgical technologies named after academician Published in the Ministry of health.
Relevant data on the situation of COVID-19 in Russia and the world presented on the portal stopmanager.of the Russian Federation.